These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Development of immobilized enzyme reactors based on human recombinant cytochrome P450 enzymes for phase I drug metabolism studies. Nicoli R; Bartolini M; Rudaz S; Andrisano V; Veuthey JL J Chromatogr A; 2008 Oct; 1206(1):2-10. PubMed ID: 18556005 [TBL] [Abstract][Full Text] [Related]
10. Scalable lipid droplet microarray fabrication, validation, and screening. Bell TN; Kusi-Appiah AE; Tocci V; Lyu P; Zhu L; Zhu F; Van Winkle D; Cao H; Singh MS; Lenhert S PLoS One; 2024; 19(7):e0304736. PubMed ID: 38968248 [TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450 3A4 and a carbon nanofiber modified film electrode as a platform for the simple evaluation of drug metabolism and inhibition reactions. Xue Q; Kato D; Kamata T; Guo Q; You T; Niwa O Analyst; 2013 Nov; 138(21):6463-8. PubMed ID: 24027778 [TBL] [Abstract][Full Text] [Related]
12. Development of an Evidence biochip array kit for the multiplex screening of more than 20 anthelmintic drugs. Porter J; O'Loan N; Bell B; Mahoney J; McGarrity M; McConnell RI; Fitzgerald SP Anal Bioanal Chem; 2012 Jul; 403(10):3051-6. PubMed ID: 22566198 [TBL] [Abstract][Full Text] [Related]
13. Luminometric method for screening retroviral protease inhibitors. Horáková D; Rumlová M; Pichová I; Ruml T Anal Biochem; 2005 Oct; 345(1):96-101. PubMed ID: 16125122 [TBL] [Abstract][Full Text] [Related]
15. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936 [TBL] [Abstract][Full Text] [Related]
16. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. Kariv I; Fereshteh MP; Oldenburg KR J Biomol Screen; 2001 Apr; 6(2):91-9. PubMed ID: 11689103 [TBL] [Abstract][Full Text] [Related]
17. Nanodroplet microarrays for high-throughput enzyme screening. Aw KL; Yao SQ; Uttamchandani M Methods Mol Biol; 2010; 669():79-93. PubMed ID: 20857359 [TBL] [Abstract][Full Text] [Related]
18. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. Doshi U; Li AP J Biomol Screen; 2011 Sep; 16(8):903-9. PubMed ID: 21832258 [TBL] [Abstract][Full Text] [Related]
20. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]